GSK’s older adult … vaccine candidate shows 94.1% reduction in severe RSV disease and overall vaccine efficacy of 82.6%
Discussion in 'Other health news and research' started by cassava7, Oct 13, 2022.
Discussion in 'Other health news and research' started by cassava7, Oct 13, 2022.